SCHEMBL13465148

SCHEMBL13465148

COC(=O)c1cccc(Nc2ccc(C)cc2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TCF4 P15884 1/20 0.63
CTNNB1 P35222 1/20 0.63
MAPT P10636 5/20 0.57
ALDH1A1 P00352 3/20 0.57
HPGD P15428 1/20 0.57
TP53 P04637 2/20 0.57
LMNA P02545 2/20 0.57
TSHR P16473 1/20 0.57
MAPK1 P28482 1/20 0.57
RAB9A P51151 5/20 0.56
POLB P06746 1/20 0.56
NPC1 O15118 4/20 0.55
TDP1 Q9NUW8 1/20 0.55
GPR17 Q13304 1/20 0.55
MEN1 O00255 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1459528 0.89 RAB9A (0.58) MAPTALDH1A1TP53LMNATSHR
SCHEMBL1745412 0.88 RAB9A (0.71) MAPTALDH1A1HPGDTP53LMNA
SCHEMBL5928165 0.86 TCF4 (0.64) TCF4CTNNB1MAPTALDH1A1HPGD
SCHEMBL9560810 0.86 MEN1 (0.57) MAPTALDH1A1TP53LMNATSHR
SCHEMBL27928486 0.86 ROCK1 (0.58) MAPTALDH1A1HPGDTP53LMNA
SCHEMBL13465147 0.86 RAB9A (0.55) MAPTALDH1A1HPGDTP53LMNA
SCHEMBL13465390 0.86 RAB9A (0.55) MAPTALDH1A1TP53LMNATSHR
SCHEMBL5928751 0.86 RAB9A (0.74) MAPTALDH1A1TP53LMNATSHR
SCHEMBL22453217 0.86 RAB9A (0.59) MAPTALDH1A1HPGDTP53LMNA
SCHEMBL15871704 0.84 RAB9A (0.76) TCF4CTNNB1MAPTALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10071953-B2 Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-09-11 US disclosed
US-20160159731-A1 Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof UNIV PENNSYLVANIA (US) 2016-06-09 US disclosed
US-20160159731-A1 Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof UNIV PENNSYLVANIA (US) 2016-06-09 US disclosed
US-20160159731-A1 Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof UNIV PENNSYLVANIA (US) 2016-06-09 US disclosed
US-9271961-B2 Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-03-01 US disclosed
US-9271961-B2 Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-03-01 US disclosed
US-9271961-B2 Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-03-01 US disclosed
US-20140107085-A1 Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-04-17 US disclosed
US-20140107085-A1 Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-04-17 US disclosed
US-20140107085-A1 Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-04-17 US disclosed
WO-2012142208-A1 BIFUNCTIONAL AKR1C3 INHIBITORS/ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2012-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10071953-B2 Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof AR, AKR1C3, AKR1C2 TCF4 3478/4885CTNNB1 2632/4885MAPT 3383/4885
US-20140107085-A1 Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof AR, AKR1C3, AKR1C2 TCF4 3478/4885CTNNB1 2632/4885MAPT 3383/4885
US-20160159731-A1 Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof AR, AKR1C3, AKR1C2 TCF4 3478/4885CTNNB1 2632/4885MAPT 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.